{
CRISPR Therapeutics AG

Companies

}
Symbol CRSP
Name CRISPR Therapeutics AG
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country Switzerland
State
City Zug
Zipcode 6300
Website http://www.crisprtx.com
Track all markets on TradingView
CRISPR Therapeutics gains momentum with Medicaid plan for gene-editing treatment
CRISPR Therapeutics has faced a 23% decline in stock value this year despite recent regulatory approvals for its gene-editing medicine, Casgevy, which treats sickle cell disease and beta-thalassemia. The high cost of $2.2 million per treatment poses accessibility challenges, but a new U.S. government plan aims to help Medicaid patients afford it, potentially expanding access for many. However, the company reported only $1.6 million in revenue in the first nine months, indicating slow uptake of Casgevy.
Yahoo Finance
United States Dollar Vertex Pharmaceuticals Inc CRISPR Therapeutics AG SAU BHR GBR USA Joe Biden Show more
Healthcare, Market Report
18:25 22.12.2024
CRISPR Therapeutics gains momentum with new Medicaid plan for gene therapy access
CRISPR Therapeutics has faced a challenging market, with shares down 23% year-to-date despite recent regulatory approvals for its gene-editing medicine, Casgevy, which treats sickle cell disease and beta-thalassemia. The Biden administration's new Medicaid initiative aims to improve access to Casgevy, potentially expanding its market significantly. With a projected peak annual sales exceeding $2.2 billion, the company is well-positioned for future growth, although it currently reports minimal revenue.
The Motley Fool
United States Dollar Vertex Pharmaceuticals Inc bluebird bio, Inc. CRISPR Therapeutics AG SAU USA BHR GBR Show more
Healthcare, Market Report
18:25 22.12.2024
crispr therapeutics gains momentum with new fda designation for cell therapy
CRISPR Therapeutics has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its cell therapy CTX112, aimed at treating relapsed or refractory B-cell malignancies. This designation allows for a potentially expedited approval process, offering financial flexibility and a simpler manufacturing approach. While the new development is promising, the success of CTX112 still hinges on convincing safety and efficacy data in clinical trials.
@AOL
Vertex Pharmaceuticals Inc Apple Inc. NVIDIA Corporation Netflix, Inc. CRISPR Therapeutics AG USA Alex Carchidi Show more
Healthcare, Market Report
15:30 20.12.2024
crispr therapeutics gains momentum with new fda designation for cell therapy
CRISPR Therapeutics has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its cell therapy CTX112, aimed at treating relapsed or refractory B-cell malignancies. This designation allows for expedited development and potential early revenue generation, enhancing the company's financial flexibility. The off-the-shelf manufacturing approach of CTX112 could lead to more consistent patient responses, positioning CRISPR favorably for future growth despite inherent clinical trial risks.
The Motley Fool
United States Dollar Vertex Pharmaceuticals Inc CRISPR Therapeutics AG CHE
Healthcare, Market Report
15:30 20.12.2024
insider sales and hedge fund activity at crispr therapeutics raise eyebrows
CRISPR Therapeutics insiders have sold 50,382 shares worth $2.74 million in the last 90 days, with insiders owning 4.10% of the company. Institutional investors hold 69.20% of the stock, while analysts maintain a "Hold" rating, with a consensus target price of $77.93. The company's recent earnings report showed a loss of $1.01 per share, exceeding expectations, but revenue fell short at $0.60 million.
MarketBeat
CRISPR Therapeutics AG USA James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
15:09 20.12.2024
crispr therapeutics shares hit new low amid mixed analyst ratings
Larson Financial Group LLC increased its stake in CRISPR Therapeutics by 95.5% in Q2, now holding 565 shares valued at $31,000. Other institutional investors also made significant investments, with ownership among them at 69.20%. CRISPR Therapeutics, focused on gene-editing for serious diseases, recently hit a 52-week low of $40.61, with analysts giving it a consensus "Hold" rating and an average price target of $77.93.
MarketBeat
CRISPR Therapeutics AG USA James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
12:18 19.12.2024
promising gene therapy stocks to watch in the evolving biotech landscape
The biotech sector is witnessing renewed interest in gene therapies, particularly following recent FDA approvals. Companies like Sarepta Therapeutics, CRISPR Therapeutics, and Voyager Therapeutics are positioned for growth in 2025, with Sarepta's Elevidys leading the way as the first gene therapy for Duchenne muscular dystrophy. The company is also expanding its pipeline with new treatments for other neuromuscular disorders.
Yahoo Finance
Voyager Therapeutics, Inc. CRISPR Therapeutics AG Sarepta Therapeutics, Inc. USA Show more
Healthcare, Market Report
14:59 17.12.2024
crispr therapeutics experiences drop in short interest and mixed analyst ratings
CRISPR Therapeutics AG (NASDAQ:CRSP) experienced a 6.4% decline in short interest in November, totaling 18,150,000 shares. Analysts have mixed ratings, with a consensus "Hold" and a target price of $77.93, while CEO Samarth Kulkarni sold 30,000 shares, reducing his stake by 13.24%. The company reported a quarterly EPS of ($1.01), surpassing estimates, but revenue fell short at $0.60 million.
MarketBeat
CRISPR Therapeutics AG USA James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
04:20 17.12.2024
Crispr Therapeutics sees bullish call volume ahead of earnings report
Crispr Therapeutics (CRSP) is experiencing above-normal call volume, indicating bullish sentiment, with 5,198 calls traded—1.3 times the expected amount. Implied volatility has risen over 3 points to 55.13%, with the Jan-25 50 calls and Dec-24 47 calls being the most active. The Put/Call Ratio stands at 0.20, and earnings are anticipated on February 19th.
TipRanks Financial
CRISPR Therapeutics AG
Finance & Economy, Market Report
21:25 16.12.2024
dow jones rises as bitcoin stocks gain and ai investments fluctuate
Super Micro Computer's stock fell nearly 5% amid concerns of potential delisting from the Nasdaq, following a series of financial reporting issues and the resignation of its accounting firm, Ernst & Young. The company is seeking to raise capital through equity and debt to stabilize its finances. Despite recent declines, the stock is still up about 23% this year.
Investor's Business Daily
United States Dollar Honeywell International Inc. Teradyne, Inc. CRISPR Therapeutics AG NVIDIA Corporation Beam Therapeutics Inc. Tempus AI, Inc Tesla, Inc. NIKE, Inc. Palantir Technologies Inc. Invesco QQQ Trust Micron Technology, Inc. Broadcom Inc. Super Micro Computer, Inc. USA Michael Larkin Show more
Finance & Economy, Market Report
17:06 16.12.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Banking Regulations Central Bank Actions Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Cryptocurrency & Blockchain Regulations Mergers & Acquisitions Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Cryptocurrency Regulations Emerging Startups SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK AUT LIE KOR NGA FIN COL VGB
Companies:
Credit Suisse Real Estate Fund Siat Coinbase Global, Inc. BlackRock, Inc. Solana USD Ripples USD Ethereum USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Gary Gensler Thomas Jordan Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.